Fundraising Fox
Slate Medicines
Boston, US · Founded 2024 · Delaware corporation · 9 employees on LinkedIn · 3 known investors
Find your way into Slate Medicines
Sign up to see every warm intro you have to Slate Medicines
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Slate Medicines team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Slate Medicines is a clinical-stage biotechnology company. The page profiles an executive but provides limited detail on the company's specific therapeutic focus.
Founders & leadership
SP
Sara PachecoExecutive
Board
TL
Tim LohoffBoard director
CX
AL
Investors · 3
Foresite Capitallisted by Foresite CapitalWest Hollywood
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
VenrockreportedPalo Alto · $500K – $10M
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$10M disclosed across 1 round · 2026
▶$10MraisedMar 2026 · 6 investors · PharmaceuticalsRule 506(b)
▶$10MraisedMar 2026 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sara PachecoExecutive Officer
- Tim LohoffDirector
- Cindy XiongDirector
- Neil BuckleyExecutive Officer, Director
- Gregory Frank OakesExecutive Officer
- Andrew LevinDirector
- Offering amount
- $130M
- Amount sold
- $10M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Milestone PharmaceuticalsMilestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.
Slate BioSlate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases. The company focuses on advancing immunology treatments for patients with autoimmune conditions.
Rhythm PharmaceuticalsRhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway. The company's lead product, IMCIVREE (setmelanotide), is FDA-approved to treat severe obesity caused by genetic impairments in the hypothalamus.
Honeybee HealthHoneybee Health is a mail-order pharmacy based in California that fills prescription and over-the-counter medications, selling generic drugs at transparent, low prices without insurance. It serves patients directly as well as telehealth platforms and practitioners through a prescription fulfillment partnership program, and can also fill prescriptions for pets.
PrescriberPointPrescriberPoint operates an AI-enabled medication access platform that helps clinicians get patients onto prescribed therapies by providing prescribing support, coverage and cost-savings lookups in one place. It serves healthcare providers in the medication access and prescribing space.
Companies working in the same space as Slate Medicines.
Frequently asked questions
- What does Slate Medicines do?
- Slate Medicines is a clinical-stage biotechnology company. The page profiles an executive but provides limited detail on the company's specific therapeutic focus.
- Who are Slate Medicines's investors?
- Slate Medicines's investors include Foresite Capital, RA Capital, Venrock.
- How much funding has Slate Medicines raised?
- Slate Medicines has disclosed $10M raised across 1 round.
- Where is Slate Medicines headquartered?
- Slate Medicines is headquartered in Boston, US.